From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Response mBev
Activity BT
CR
PR
SD
PD
n
n(%)
4 CR
4 (100)
18 PR
12 (66.7)
6 (33.3)
13 SD
1 (7.7)
10 (76.9)
2 (15.4)